The c-Met-targeting peptide was designed as non-standard macrocyclic form. The fluorescein-labeled macrocyclic peptides with optimal dose and time were bound in c-Met positive gastric cancer cells. The peptides specifically targeted c-Met-expressing gastric cancers in vivo.